Our portfolio company Sirius Medical secures growth funding from new and existing investors to further develop the Sirius Pintuition portfolio and expand international sales
Eindhoven, 4th of February 2025 – Our portfolio company Sirius Medical, a leading medtech company and market leader in oncological surgical marker navigation, has raised €10 million in funding on World Cancer Day. This investment round was led by Invest-NL and Nextgen Ventures, with support from De Groot Family Office and existing investors Brabant Development Agency (BOM), Holland Capital, Curie Capital, Team Holmium, and Sirius Medical’s team.
World Cancer Day is a poignant reminder of the ongoing fight against cancer, and this milestone reflects Sirius Medical’s commitment to enhancing cancer care. Praised by breast cancer surgeons worldwide, the Sirius Pintuition® surgical navigation platform enables simple, best-in-class wire-free localization for breast-conserving surgery in any hospital. This latest funding round empowers Sirius Medical to enhance the Sirius Pintuition system and GPSDetect™ software platform, focusing on usability and intuitiveness, and extending its applications. Additionally, the investment will substantially bolster the sales infrastructure and support expansion into new markets.
“Announcing this funding milestone on World Cancer Day underscores the urgency of our mission to improve cancer care globally,” says Bram Schermers, CEO of Sirius Medical. “This funding round, in the current fundraising environment, is a clear testament to the talent of the Sirius Medical team, and the Pintuition technology that we have developed. We are proud to continue contributing to the fight against cancer and look forward to the next phase of growth for Sirius Medical. We will have more exciting news to announce soon.”
“From Holland Capital, we have been supporting Sirius Medical for many years to bridge the notorious ‘valley of death,’” said Jan Frens van Giessel, partner at Holland Capital. “Many young companies in medical technology fail due to a lack of funding, as reported by Financieele Dagblad a few weeks ago. For investors, investing in medical technology is risky because the development and sales processes are complex, uncertain, and lengthy. We experience this at Holland Capital as well, but when a company manages to distinguish itself and achieves key technical and commercial milestones, we do everything we can to arrange financing. This is also the case with Sirius Medical.”
“We have seen Sirius Medical grow over the years into a successful med-tech scale-up, with sales in the US, UK, almost all EU countries, and Australia. We are proud of the impressive results the Sirius Medical team has achieved. We welcome the new investors, NextGen and InvestNL, so that together we can make this Dutch healthcare innovation available to women with breast cancer worldwide,” said Jan Frens van Giessel, partner at Holland Capital.
About World Cancer Day
World Cancer Day, observed on February 4th, is a global initiative to raise awareness, inspire action, and work together to reduce the impact of cancer worldwide.
About Sirius Medical
With its roots in the Netherlands Cancer Institute, Sirius Medical is dedicated to improving care for cancer patients by delivery of unsurpassed, yet affordable solutions that enable precise and efficient removal of tumors. Sirius Pintuition is precise, simple, affordable and both CE marked, and FDA cleared. Sirius Medical is rapidly expanding with over 250 centers and 35.000 procedures globally.
Holland Venture en BOM investeren in CytoSMART: digitale microscopie in the cloud
Amsterdam/Tilburg, 13 juni 2016 - Investeringsmaatschappij Holland Venture investeert samen met de Brabantse Ontwikkelings Maatschappij (BOM) in CytoSMART Technologies. CytoSMART, opgericht in 2012 onder de naam CytoMATE, is een spin-off van de TU/e. Het bedrijf...
Holland Venture and BOM invest in CytoSMART: digital microscopic imaging in the cloud
Amsterdam/Tilburg, 13 June 2016 - Private equity firm Holland Venture and the Brabant Development Agency (BOM) are together investing in CytoSMART Technologies. Founded in 2012 under the name CytoMATE, CytoSMART is a spin-off of Eindhoven University of Technology...
Humeca opent officieel zusterbedrijf Humeca, Inc. in de Verenigde Staten
De opening volgt op een gestage groei van de vraag en het aanbod van hun producten wereldwijd en stelt Humeca in staat om hun distributienetwerk in de Verenigde Staten uit te breiden. De huidtransplantatie producten zijn levensreddend voor de behandeling van...
Humeca officially launches sister company Humeca, Inc. in the USA
Amsterdam, 12 februari 2016 - The launch follows a steady growth in demand and supply of their products worldwide and enables Humeca to expand their distribution network in the United States. The skin grafting products are life-saving for the treatment of burn...
Holland Venture investeert fors in groei marketingtechnologiebedrijf Relay42
Amsterdam, 8 december 2015 – Investeringsmaatschappij Holland Venture en de voormalige topmanager van Booking.com investeren gezamenlijk enkele miljoenen in de Nederlandse datamanagementspecialist Relay42. Met het innovatieve datamanagementplatform van Relay42 kunnen...
Holland Venture provides substantial investment to marketing technology company Relay42
Amsterdam, December 8th 2015 – Holland Venture and a former Board Executive of Booking.com have invested several millions of euros in the Dutch data management specialist Relay42. Marketers use Relay42’s innovative data management platform to coordinate the customer...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl